Skip to main content
Candel Therapeutics, Inc. logo

Candel Therapeutics, Inc. — Investor Relations & Filings

Ticker · CADL ISIN · US1374041093 US Manufacturing
Open in API
Filings indexed 368 across all filing types
Latest filing 2022-08-10 Regulatory Filings
Country US United States of America
Listing US CADL

About Candel Therapeutics, Inc.

https://www.candeltx.com/

Candel Therapeutics, Inc. is a company developing viral immunotherapies designed to activate a patient's immune system to fight cancer. Its approach utilizes two main platforms based on engineered adenovirus and Herpes Simplex Virus (HSV). These investigational, off-the-shelf therapies are administered directly into tumors to induce immunogenic cell death. This process is intended to stimulate a personalized, systemic, and durable anti-tumor response specific to the individual's cancer. The company aims to create treatments that are both efficacious and well-tolerated for patients across various disease stages.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2022
Regulatory Filings
2022-08-10 English
S-3
Capital/Financing Update Classification · 100% confidence The document is a Form S-3 Registration Statement filed with the SEC, which is used by companies to register securities for sale to the public. It includes a base prospectus for offering up to $200 million of various securities including common stock, preferred stock, debt securities, warrants, and units. The document is a detailed registration statement and prospectus, not a financial report, earnings release, or management discussion. It is clearly related to capital raising activities and financing. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed offering information, consistent with a capital raising filing rather than a brief announcement or regulatory filing.
2022-08-05 English
10-Q
Interim / Quarterly Report Q2 2022
2022-08-05 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 5, 2022, reporting the financial results for the quarter ended June 30, 2022. It includes a press release as an exhibit but does not contain the full financial statements or detailed financial analysis itself. The text explicitly states that the press release is furnished as an exhibit and that the information is not deemed "filed" for certain regulatory purposes. The document length is 3523 characters, which is relatively short and consistent with a current report filing rather than a full quarterly or annual report. The Form 8-K is typically used for current reports on material events, including earnings announcements, but the full financial details are usually in the press release or subsequent filings. Given these factors, this document is best classified as an Earnings Release (ER) announcement within a Form 8-K filing, as it announces quarterly financial results but does not itself contain comprehensive financial statements or analysis required for an Interim/Quarterly Report (IR).
2022-08-05 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K current report filed with the SEC, dated July 26, 2022, by Candel Therapeutics, Inc. The key content is the announcement of resignations and appointments of members of the Board of Directors, including details about their qualifications, committee assignments, and compensation. There is no financial data or discussion of financial results, nor is this a full annual or quarterly report. The primary focus is on changes in the company's board of directors. According to the filing definitions, announcements of changes in the company's board or senior management fall under Board/Management Information (MANG). The document length is about 5,386 characters, which is consistent with a detailed management change announcement. Therefore, the correct classification is MANG with high confidence.
2022-08-01 English
8-K
Investor Presentation Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated June 4, 2022, by Candel Therapeutics, Inc. It reports on an investor presentation held on the same date, which is furnished as Exhibit 99.1. The text explicitly states that the investor presentation is furnished and not filed, and the document contains no financial statements or detailed financial data itself. The document length is 3698 characters, which is relatively short and consistent with an announcement rather than a full report. The key content is the announcement of an investor presentation, not the presentation itself or a detailed financial report. Therefore, this document is best classified as an Investor Presentation (IP) filing type, as it primarily serves to provide information about the investor presentation event and includes the presentation as an exhibit.
2022-06-06 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.